Abstract
Despite isolated reports of dramatic hemodynamic and clinical improvement over the past 30 years, most patients with primary pulmonary hypertension fail to benefit from treatment with vasodilator drugs and many develop serious adverse reactions. The failure of this approach strongly suggests that pulmonary vasoconstriction does not play an important role in the pathogenesis of this disorder.
Original language | English (US) |
---|---|
Pages (from-to) | 265S-268S |
Journal | CHEST |
Volume | 88 |
Issue number | 4 SUPPL. |
DOIs | |
State | Published - 1985 |
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
- Critical Care and Intensive Care Medicine
- Cardiology and Cardiovascular Medicine